Synaptogenix Statistics
Total Valuation
Synaptogenix has a market cap or net worth of $5.61 million. The enterprise value is -$22.66 million.
| Market Cap | 5.61M |
| Enterprise Value | -22.66M |
Important Dates
The last earnings date was Wednesday, May 15, 2024.
| Earnings Date | May 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Synaptogenix has 1.23 million shares outstanding. The number of shares has increased by 245.45% in one year.
| Shares Outstanding | 1.23M |
| Shares Change (YoY) | +245.45% |
| Shares Change (QoQ) | +122.43% |
| Owned by Insiders (%) | 2.14% |
| Owned by Institutions (%) | 3.10% |
| Float | 1.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.25 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.58, with zero debt.
| Current Ratio | 4.58 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.90% and return on invested capital (ROIC) is -32.12%.
| Return on Equity (ROE) | -49.90% |
| Return on Assets (ROA) | -38.70% |
| Return on Capital (ROIC) | -32.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.45M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.81% in the last 52 weeks. The beta is 1.51, so Synaptogenix's price volatility has been higher than the market average.
| Beta (1Y) | 1.51 |
| 52-Week Price Change | -78.81% |
| 50-Day Moving Average | 4.68 |
| 200-Day Moving Average | 6.61 |
| Relative Strength Index (RSI) | 46.95 |
| Average Volume (30 Days) | 46,666 |
Short Selling Information
The latest short interest is 25,972, so 2.11% of the outstanding shares have been sold short.
| Short Interest | 25,972 |
| Short Previous Month | 30,178 |
| Short % of Shares Out | 2.11% |
| Short % of Float | 2.16% |
| Short Ratio (days to cover) | 0.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.08M |
| Pretax Income | -4.53M |
| Net Income | -12.23M |
| EBITDA | -4.53M |
| EBIT | -4.53M |
| Earnings Per Share (EPS) | -$28.41 |
Balance Sheet
The company has $28.27 million in cash and no debt, giving a net cash position of $28.27 million or $22.92 per share.
| Cash & Cash Equivalents | 28.27M |
| Total Debt | n/a |
| Net Cash | 28.27M |
| Net Cash Per Share | $22.92 |
| Equity / Book Value | 22.05M |
| Book Value Per Share | 17.88 |
| Working Capital | 22.53M |
Cash Flow
In the last 12 months, operating cash flow was -$5.31 million and capital expenditures -$669, giving a free cash flow of -$5.31 million.
| Operating Cash Flow | -5.31M |
| Capital Expenditures | -669 |
| Free Cash Flow | -5.31M |
| FCF Per Share | -$5.12 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Synaptogenix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -245.45% |
| Shareholder Yield | -245.45% |
| Earnings Yield | -217.90% |
| FCF Yield | -94.63% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 5, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Apr 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |